According to Sihuan Pharmaceutical Holdings Group Ltd.’s (Sihuan Pharm) monthly return for the period ended 31 May 2026, the company executed share repurchases that reduced its outstanding share count while maintaining a sufficient public float under Hong Kong Listing Rules.

• Share capital structure – Authorised capital stayed unchanged at 100.00 billion ordinary shares with a par value of HKD 0.01, representing HKD 1.00 billion in authorised share capital.

• Issued and treasury shares – Issued shares (excluding treasury stock) fell by 20.00 million to 9.13 billion, reflecting a 0.22% month-on-month reduction. – Treasury shares rose correspondingly by 20.00 million to 204.01 million, equivalent to 2.19% of the total 9.33 billion shares in issue. – The decrease resulted from two on-market buybacks: 1) 13 May 2026: 10.00 million shares at an average HKD 1.0931 each. 2) 18 May 2026: 10.00 million shares at an average HKD 1.0685 each. The combined cash outlay for these repurchases totalled approximately HKD 21.62 million.

• Share option schemes – Outstanding options were unchanged at 68.09 million units (60.59 million exercisable at HKD 0.972 and 7.50 million at HKD 2.22). – No options were granted, exercised, cancelled or lapsed during the month. – The schemes still allow up to 844.95 million additional shares to be issued upon future option grants and exercises.

• Compliance status Sihuan Pharm confirmed that it met the Main Board’s minimum 25% public-float requirement as at 31 May 2026.

Overall, May’s activity centred on measured share repurchases, modestly lowering the free-float share base while preserving regulatory compliance and leaving the company’s authorised capital and option pools intact.